Application note: Monitoring Aggregation of Antibody-Drug Conjugates
Posted: 30 July 2019 | | No comments yet
Prediction of Aggregation Propensity and Monitoring of Aggregation of Antibody-Drug Conjugates (ADC).
Innate Pharma has developed an antibody-drug conjugate (ADC) coupling technology. To validate the technology concept for clinical applications, the stability of unglycosylated SGN30 Q and S mutants coupled to the MMAE toxin by either one-step (SGN30 Q/S-linker-vcMMAE) or two-step technology (SGN30 Q/S-Linker-Click-Linker-vcMMAE) was compared to the first FDA-approved ADC, ADCETRIS® and evaluated. Utilizing the ProteoStat® Thermal Shift Assay, the temperatures of aggregation were determined and used to establish an aggregation propensity prediction ladder.